ArticleScientific reports2025
Effectiveness of enoxaparin in preventing intraoperative fibrin formation during DMEK assessed in a before-and-after study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To demonstrate that enoxaparin in the irrigation saline solution can effectively prevent intraoperative fibrin formation (IFF) during Descemet membrane endothelial keratoplasty (DMEK) surgery without compromising graft viability, visual recovery, or intraoperative safety. A "before-and-after" study was conducted, comparing the rate of IFF in a prospective cohort of DMEK cases treated with enoxaparin to a retrospective cohort without treatment. Donor cornea characteristics, surgical data, rebubbling rate, final endothelial cell density (ECD), and best corrected visual acuity (BCVA) were analyzed. A total of 265 cases were analyzed. The incidence of IFF was 5.43% in the cohort without enoxaparin and zero in the enoxaparin-treated cohort. The risk ratio for enoxaparin use was 0 (confidence interval: 0), with a risk difference of -0.054 and a number needed to treat (NNT) of 18.42 cases to prevent one IFF event. No significant differences were found in baseline patients features or surgical aspects. The rebubbling rate was 16.98%, with no statistically significant difference between groups. No significant differences were observed in final ECD or BCVA between groups. In addition, no intraoperative complications or intraocular bleeding occurred with enoxaparin administration. Enoxaparin is a safe, effective, and cost-efficient prophylaxis for preventing IFF during DMEK surgery. It impedes the development of IFF, which may require a new and costly transplant when it occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.